share_log

Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11

Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11

Roth MKM 维持对Cyclacel Pharmicals的买入,将目标股价下调至11美元
Benzinga ·  05/03 10:13

Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target from $21 to $11.

罗斯MKM分析师乔纳森·阿肖夫维持Cyclacel Pharmicals(纳斯达克股票代码:CYCC)的买入并将目标股价从21美元下调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发